BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 21264845)

  • 1. Clinical outcome of triple negative breast cancer in BRCA1 mutation carriers and noncarriers.
    Lee LJ; Alexander B; Schnitt SJ; Comander A; Gallagher B; Garber JE; Tung N
    Cancer; 2011 Jul; 117(14):3093-100. PubMed ID: 21264845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns of recurrence and metastasis in BRCA1/BRCA2-associated breast cancers.
    Song Y; Barry WT; Seah DS; Tung NM; Garber JE; Lin NU
    Cancer; 2020 Jan; 126(2):271-280. PubMed ID: 31581314
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
    Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response to neoadjuvant systemic therapy for breast cancer in BRCA mutation carriers and noncarriers: a single-institution experience.
    Arun B; Bayraktar S; Liu DD; Gutierrez Barrera AM; Atchley D; Pusztai L; Litton JK; Valero V; Meric-Bernstam F; Hortobagyi GN; Albarracin C
    J Clin Oncol; 2011 Oct; 29(28):3739-46. PubMed ID: 21900106
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations.
    Rennert G; Bisland-Naggan S; Barnett-Griness O; Bar-Joseph N; Zhang S; Rennert HS; Narod SA
    N Engl J Med; 2007 Jul; 357(2):115-23. PubMed ID: 17625123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Breast Cancer Survival of BRCA1/BRCA2 Mutation Carriers in a Hospital-Based Cohort of Young Women.
    Schmidt MK; van den Broek AJ; Tollenaar RA; Smit VT; Westenend PJ; Brinkhuis M; Oosterhuis WJ; Wesseling J; Janssen-Heijnen ML; Jobsen JJ; Jager A; Voogd AC; van Leeuwen FE; van 't Veer LJ
    J Natl Cancer Inst; 2017 Aug; 109(8):. PubMed ID: 28376189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.
    van den Broek AJ; Schmidt MK; van 't Veer LJ; Oldenburg HSA; Rutgers EJ; Russell NS; Smit VTHBM; Voogd AC; Koppert LB; Siesling S; Jobsen JJ; Westenend PJ; van Leeuwen FE; Tollenaar RAEM
    Ann Surg; 2019 Aug; 270(2):364-372. PubMed ID: 29727326
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
    Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
    Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline BRCA mutation and outcome in young-onset breast cancer (POSH): a prospective cohort study.
    Copson ER; Maishman TC; Tapper WJ; Cutress RI; Greville-Heygate S; Altman DG; Eccles B; Gerty S; Durcan LT; Jones L; Evans DG; Thompson AM; Pharoah P; Easton DF; Dunning AM; Hanby A; Lakhani S; Eeles R; Gilbert FJ; Hamed H; Hodgson S; Simmonds P; Stanton L; Eccles DM
    Lancet Oncol; 2018 Feb; 19(2):169-180. PubMed ID: 29337092
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breast cancer prognosis in BRCA1 and BRCA2 mutation carriers: an International Prospective Breast Cancer Family Registry population-based cohort study.
    Goodwin PJ; Phillips KA; West DW; Ennis M; Hopper JL; John EM; O'Malley FP; Milne RL; Andrulis IL; Friedlander ML; Southey MC; Apicella C; Giles GG; Longacre TA
    J Clin Oncol; 2012 Jan; 30(1):19-26. PubMed ID: 22147742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival and recurrence after breast cancer in BRCA1/2 mutation carriers.
    El-Tamer M; Russo D; Troxel A; Bernardino LP; Mazziotta R; Estabrook A; Ditkoff BA; Schnabel F; Mansukhani M
    Ann Surg Oncol; 2004 Feb; 11(2):157-64. PubMed ID: 14761918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of breast cancer recurrence and contralateral breast cancer in relation to BRCA1 and BRCA2 mutation status following breast-conserving surgery and radiotherapy.
    Kirova YM; Stoppa-Lyonnet D; Savignoni A; Sigal-Zafrani B; Fabre N; Fourquet A;
    Eur J Cancer; 2005 Oct; 41(15):2304-11. PubMed ID: 16140006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.
    Pierce LJ; Levin AM; Rebbeck TR; Ben-David MA; Friedman E; Solin LJ; Harris EE; Gaffney DK; Haffty BG; Dawson LA; Narod SA; Olivotto IA; Eisen A; Whelan TJ; Olopade OI; Isaacs C; Merajver SD; Wong JS; Garber JE; Weber BL
    J Clin Oncol; 2006 Jun; 24(16):2437-43. PubMed ID: 16636335
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Survival After Breast-Conserving Therapy vs Mastectomy Among Patients With or Without the BRCA1/2 Variant in a Large Series of Unselected Chinese Patients With Breast Cancer.
    Wan Q; Su L; Ouyang T; Li J; Wang T; Fan Z; Fan T; Lin B; Xie Y
    JAMA Netw Open; 2021 Apr; 4(4):e216259. PubMed ID: 33890992
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
    Bayraktar S; Gutierrez-Barrera AM; Liu D; Tasbas T; Akar U; Litton JK; Lin E; Albarracin CT; Meric-Bernstam F; Gonzalez-Angulo AM; Hortobagyi GN; Arun BK
    Breast Cancer Res Treat; 2011 Nov; 130(1):145-53. PubMed ID: 21830012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Breast cancer risk in BRCA1/2 mutation carriers and noncarriers under prospective intensified surveillance.
    Engel C; Fischer C; Zachariae S; Bucksch K; Rhiem K; Giesecke J; Herold N; Wappenschmidt B; Hübbel V; Maringa M; Reichstein-Gnielinski S; Hahnen E; Bartram CR; Dikow N; Schott S; Speiser D; Horn D; Fallenberg EM; Kiechle M; Quante AS; Vesper AS; Fehm T; Mundhenke C; Arnold N; Leinert E; Just W; Siebers-Renelt U; Weigel S; Gehrig A; Wöckel A; Schlegelberger B; Pertschy S; Kast K; Wimberger P; Briest S; Loeffler M; Bick U; Schmutzler RK;
    Int J Cancer; 2020 Feb; 146(4):999-1009. PubMed ID: 31081934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of triple-negative breast cancer in patients with a BRCA1 mutation: results from a population-based study of young women.
    Lee E; McKean-Cowdin R; Ma H; Spicer DV; Van Den Berg D; Bernstein L; Ursin G
    J Clin Oncol; 2011 Nov; 29(33):4373-80. PubMed ID: 22010008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term prognosis of early-onset breast cancer in a population-based cohort with a known BRCA1/2 mutation status.
    Nilsson MP; Hartman L; Idvall I; Kristoffersson U; Johannsson OT; Loman N
    Breast Cancer Res Treat; 2014 Feb; 144(1):133-42. PubMed ID: 24477976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of BRCA1- and BRCA2-related mutations on ovarian and breast cancer survival: a meta-analysis.
    Zhong Q; Peng HL; Zhao X; Zhang L; Hwang WT
    Clin Cancer Res; 2015 Jan; 21(1):211-20. PubMed ID: 25348513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.
    Pierce LJ; Strawderman M; Narod SA; Oliviotto I; Eisen A; Dawson L; Gaffney D; Solin LJ; Nixon A; Garber J; Berg C; Isaacs C; Heimann R; Olopade OI; Haffty B; Weber BL
    J Clin Oncol; 2000 Oct; 18(19):3360-9. PubMed ID: 11013276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.